<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03118596</url>
  </required_header>
  <id_info>
    <org_study_id>UHCoventryNHS</org_study_id>
    <nct_id>NCT03118596</nct_id>
  </id_info>
  <brief_title>Fibre-optic Guided Tracheal Intubation Through SADs</brief_title>
  <official_title>Fibre-optic Guided Tracheal Intubation Through Supraglottic Airway Devices - a Randomised Comparison Between I-gel and the LMA ProtectorTM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Coventry and Warwickshire NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospitals Coventry and Warwickshire NHS Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to establish which of the two second generation Supraglottic Airway Devices,
      the I-gel or the the laryngeal ask airway (LMA) Protector, is best suited to be used as a
      conduit to fibreoptic bronchoscope assisted tracheal intubation. The primary outcome of this
      will be the time to complete the tracheal intubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tracheal intubation through a supraglottic airway device (SAD) is a well-established
      technique in the management of patients with a difficult airway. The technique can be used in
      patients in whom difficult intubation is expected, or in situations when tracheal intubation
      using another method was not possible. It is now recommended that tracheal intubation through
      the SAD should be performed using a fibreoptic scope (a camera device) to minimise the risk
      of trauma to the airway, and that second generation SADs are used to minimise the risk of
      aspiration of gastric contents.

      There are two second generation SADs currently available which allow tracheal intubation: the
      I-gel and the LMA protector.

      The I-gel is a second generation supraglottic airway device widely used in anaesthesia and
      resuscitation. Fibreoptic intubation through the I-gel has been evaluated in a recent
      prospective study (1), with the first attempt success rate of 91.4%. In another study (2) of
      patients with predicted difficult airway, the success rate of the procedure at first attempt
      was 96%.

      LMA Protector is a recently introduced, improved version the LMA supreme - another second
      generation SAD. LMA supreme has been used in clinical practice for more than 10 years,
      however, tracheal intubation through the device was extremely difficult because of the small
      size of the breathing channel. The LMA Protector, has a larger breathing channel allowing the
      passage of an endotracheal tube. Compared to the I-gel, is has also got a larger gastric
      drainage tube. This allows easy suction in the event of regurgitation. Therefore, it appears
      to be superior to the I-gel in preventing the aspiration. But there are no studies comparing
      the ease of intubation through I-gel and LMA Protector

      The aim of this study is to compare the ease of performing the fibreoptic guided tracheal
      intubation through these two devices. Our hypothesis is that intubation through the I-gel is
      easier and quicker.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 24, 2017</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Intubation Time to Perform Fibreoptic Intubation</measure>
    <time_frame>less than 3 minutes</time_frame>
    <description>Time form insertion of bronchoscope through the supraglottic airway device to obtaining the capnography trace</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD Insertion Time</measure>
    <time_frame>less than 1 minute</time_frame>
    <description>Time taken to insert the supra-glottic airway device measured from insertion into the mouth until the capnography trace is obtained</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Attempts at the SAD Placement</measure>
    <time_frame>less than 2 minutes</time_frame>
    <description>Number of attempts taken to successfully place the supraglottic airway device in the oropharynx</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Ease of Placement of the SAD</measure>
    <time_frame>less than 2 minutes</time_frame>
    <description>The ease of placement of the SAD assessed by the investigator on a four point scale:
- Easy
- Moderate Difficulty 3- Severe Difficulty
4 - Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First and Second Attempt at Tracheal Intubation</measure>
    <time_frame>less than 3 minutes</time_frame>
    <description>Number of attempts at tracheal intubation. A new attempt is defined as re-insertion of the fibreoptic bronchoscope through the SAD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Quality of the View of the Vocal Cords Seen Through the SAD</measure>
    <time_frame>less than 3 minutes</time_frame>
    <description>The quality of the view of the vocal cords seen through the SAD. It will be assessed, according to the previously published system, as: grade I - full view of the vocal cord, II - partial view of the vocal cords including arytenoids, III - epiglottis only, IV - other (SAD cuff, pharynx, others)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Carinal View</measure>
    <time_frame>less than 1 minute</time_frame>
    <description>The time from insertion of fibreoptic scope into the lumen of the SAD to the visualization of the carina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Type of Airway Maneuvers Performed During Tracheal Intubation,</measure>
    <time_frame>less than 3 minutes</time_frame>
    <description>The number of tube rotations performed during tracheal intubation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Intubation; Difficult or Failed</condition>
  <condition>Laryngeal Masks</condition>
  <condition>Airway Management</condition>
  <arm_group>
    <arm_group_label>I-gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fibreoptic guided tracheal intubation through I-gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LMA Protector</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fibreoptic guided tracheal intubation through Protector</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>I-gel</intervention_name>
    <description>Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
    <arm_group_label>I-gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LMA Protector</intervention_name>
    <description>Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
    <arm_group_label>LMA Protector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢ All patients aged above 18, presenting for elective surgical procedure, where a
        supraglottic airway device can be used and left in place throughout the duration of surgery
        and requiring tracheal intubation

        Exclusion Criteria:

          -  Patients who are do not wish to take part

          -  Patients with class II obesity (BMI &gt;40)

          -  Patients below 18 years of age

          -  American Society of Anaesthesiologists (ASA 3, 4 and 5)

          -  Patients with mouth opening of less than 3 cm

          -  Patients deemed to require awake intubation

          -  Surgery involving head and neck region

          -  Surgery requiring prone position
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cyprian Mendonca, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Coventry &amp; Warwickshire NHS Trust, Clifford Bridge Road, Coventry CV2 2DX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals Coventry &amp; Warwickshire NHS Trust</name>
      <address>
        <city>Coventry</city>
        <state>West Midlands</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Frerk C, Mitchell VS, McNarry AF, Mendonca C, Bhagrath R, Patel A, O'Sullivan EP, Woodall NM, Ahmad I; Difficult Airway Society intubation guidelines working group. Difficult Airway Society 2015 guidelines for management of unanticipated difficult intubation in adults. Br J Anaesth. 2015 Dec;115(6):827-48. doi: 10.1093/bja/aev371. Epub 2015 Nov 10.</citation>
    <PMID>26556848</PMID>
  </reference>
  <reference>
    <citation>Kleine-Brueggeney M, Theiler L, Urwyler N, Vogt A, Greif R. Randomized trial comparing the i-gelâ„¢ and Magill tracheal tube with the single-use ILMAâ„¢ and ILMAâ„¢ tracheal tube for fibreoptic-guided intubation in anaesthetized patients with a predicted difficult airway. Br J Anaesth. 2011 Aug;107(2):251-7. doi: 10.1093/bja/aer103. Epub 2011 Jun 7.</citation>
    <PMID>21652616</PMID>
  </reference>
  <reference>
    <citation>El-Ganzouri, A. R., Marzouk, S., Abdelalem, N., &amp; Yousef, M. (2011). Blind versus fiberoptic laryngoscopic intubation through air Q laryngeal mask airway. Egyptian Journal of Anaesthesia, 27(4), 213-218.</citation>
  </reference>
  <reference>
    <citation>Taxak, S., Vashisht, K., Kaur, K. P., Ahlawat, G., &amp; Bhardwaj, M. (2013). A study to evaluate fibreoptic-guided intubation through the i-gel. Southern African Journal of Anaesthesia and Analgesia, 19(2), 120-123.</citation>
  </reference>
  <reference>
    <citation>Samir, E. M., &amp; Sakr, S. A. (2012). The air-Q as a conduit for fiberoptic aided tracheal intubation in adult patients undergoing cervical spine fixation: A prospective randomized study. Egyptian Journal of Anaesthesia, 28(2), 133-137.</citation>
  </reference>
  <reference>
    <citation>Jagannathan N, Sohn L, Ramsey M, Huang A, Sawardekar A, Sequera-Ramos L, Kromrey L, De Oliveira GS. A randomized comparison between the i-gelâ„¢ and the air-Qâ„¢ supraglottic airways when used by anesthesiology trainees as conduits for tracheal intubation in children. Can J Anaesth. 2015 Jun;62(6):587-94. doi: 10.1007/s12630-014-0304-9. Epub 2014 Dec 24.</citation>
    <PMID>25537736</PMID>
  </reference>
  <reference>
    <citation>Weingart SD, Levitan RM. Preoxygenation and prevention of desaturation during emergency airway management. Ann Emerg Med. 2012 Mar;59(3):165-75.e1. doi: 10.1016/j.annemergmed.2011.10.002. Epub 2011 Nov 3. Review.</citation>
    <PMID>22050948</PMID>
  </reference>
  <reference>
    <citation>Du Rand IA, Blaikley J, Booton R, Chaudhuri N, Gupta V, Khalid S, Mandal S, Martin J, Mills J, Navani N, Rahman NM, Wrightson JM, Munavvar M; British Thoracic Society Bronchoscopy Guideline Group. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013 Aug;68 Suppl 1:i1-i44. doi: 10.1136/thoraxjnl-2013-203618.</citation>
    <PMID>23860341</PMID>
  </reference>
  <reference>
    <citation>Joffe AM, Liew EC, Galgon RE, Viernes D, Treggiari MM. The second-generation air-Q intubating laryngeal mask for airway maintenance during anaesthesia in adults: a report of the first 70 uses. Anaesth Intensive Care. 2011 Jan;39(1):40-5.</citation>
    <PMID>21375088</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <results_first_submitted>August 15, 2018</results_first_submitted>
  <results_first_submitted_qc>September 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intubation</keyword>
  <keyword>tracheal</keyword>
  <keyword>airway device</keyword>
  <keyword>supra-glottic airway device</keyword>
  <keyword>fibreoptic scope</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/96/NCT03118596/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>I-gel</title>
          <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
        </group>
        <group group_id="P2">
          <title>LMA Protector</title>
          <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Failed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>I-gel</title>
          <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
        </group>
        <group group_id="B2">
          <title>LMA Protector</title>
          <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="86"/>
            <count group_id="B3" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.7" spread="15"/>
                    <measurement group_id="B2" value="54.7" spread="17"/>
                    <measurement group_id="B3" value="55" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="90"/>
                    <count group_id="B2" value="86"/>
                    <count group_id="B3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Intubation Time to Perform Fibreoptic Intubation</title>
        <description>Time form insertion of bronchoscope through the supraglottic airway device to obtaining the capnography trace</description>
        <time_frame>less than 3 minutes</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Intubation Time to Perform Fibreoptic Intubation</title>
          <description>Time form insertion of bronchoscope through the supraglottic airway device to obtaining the capnography trace</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="13.8"/>
                    <measurement group_id="O2" value="52.0" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SAD Insertion Time</title>
        <description>Time taken to insert the supra-glottic airway device measured from insertion into the mouth until the capnography trace is obtained</description>
        <time_frame>less than 1 minute</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>SAD Insertion Time</title>
          <description>Time taken to insert the supra-glottic airway device measured from insertion into the mouth until the capnography trace is obtained</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" spread="5.6"/>
                    <measurement group_id="O2" value="25.4" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Attempts at the SAD Placement</title>
        <description>Number of attempts taken to successfully place the supraglottic airway device in the oropharynx</description>
        <time_frame>less than 2 minutes</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Ease of Placement of the SAD</title>
        <description>The ease of placement of the SAD assessed by the investigator on a four point scale:
- Easy
- Moderate Difficulty 3- Severe Difficulty
4 - Failure</description>
        <time_frame>less than 2 minutes</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ease of Placement of the SAD</title>
          <description>The ease of placement of the SAD assessed by the investigator on a four point scale:
- Easy
- Moderate Difficulty 3- Severe Difficulty
4 - Failure</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Easy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe Resistance</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First and Second Attempt at Tracheal Intubation</title>
        <description>Number of attempts at tracheal intubation. A new attempt is defined as re-insertion of the fibreoptic bronchoscope through the SAD.</description>
        <time_frame>less than 3 minutes</time_frame>
        <population>IIn 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First and Second Attempt at Tracheal Intubation</title>
          <description>Number of attempts at tracheal intubation. A new attempt is defined as re-insertion of the fibreoptic bronchoscope through the SAD.</description>
          <population>IIn 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>First Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Second Attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Quality of the View of the Vocal Cords Seen Through the SAD</title>
        <description>The quality of the view of the vocal cords seen through the SAD. It will be assessed, according to the previously published system, as: grade I - full view of the vocal cord, II - partial view of the vocal cords including arytenoids, III - epiglottis only, IV - other (SAD cuff, pharynx, others)</description>
        <time_frame>less than 3 minutes</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Quality of the View of the Vocal Cords Seen Through the SAD</title>
          <description>The quality of the view of the vocal cords seen through the SAD. It will be assessed, according to the previously published system, as: grade I - full view of the vocal cord, II - partial view of the vocal cords including arytenoids, III - epiglottis only, IV - other (SAD cuff, pharynx, others)</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Carinal View</title>
        <description>The time from insertion of fibreoptic scope into the lumen of the SAD to the visualization of the carina.</description>
        <time_frame>less than 1 minute</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Carinal View</title>
          <description>The time from insertion of fibreoptic scope into the lumen of the SAD to the visualization of the carina.</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4" spread="10"/>
                    <measurement group_id="O2" value="21.9" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Type of Airway Maneuvers Performed During Tracheal Intubation,</title>
        <description>The number of tube rotations performed during tracheal intubation</description>
        <time_frame>less than 3 minutes</time_frame>
        <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
        <group_list>
          <group group_id="O1">
            <title>I-gel</title>
            <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
          </group>
          <group group_id="O2">
            <title>LMA Protector</title>
            <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Type of Airway Maneuvers Performed During Tracheal Intubation,</title>
          <description>The number of tube rotations performed during tracheal intubation</description>
          <population>In 2 patients randomly allocated to the LMA Protector group due to the failure insertion of the LMA protector the i-gel was used instead. 2 patients randomised to the LMA protector group underwent direct laryngoscopy and tracheal intubation; one due to failed insertion of both devices and one due to the failed fibreopitc-guided tracheal intubation</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tube impingement (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tube impingement (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>In two patients randomly allocated to the LMA protector group, due to failed insertion of LMA protector the I-GEL was used instead In two patients allocated to the LMA protector group, due to failed intubation direct laryngoscopy was performed.
Therefore; the final number in I-GEL group is 92 and LMA Protector Group is 86(2 were allocated to I-GEL and 2 completely failed)</desc>
      <group_list>
        <group group_id="E1">
          <title>I-gel</title>
          <description>Fibreoptic guided tracheal intubation through I-gel
I-gel: Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.</description>
        </group>
        <group group_id="E2">
          <title>LMA Protector</title>
          <description>Fibreoptic guided tracheal intubation through Protector
LMA Protector: Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="92"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="86"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Cyprian Mendonca</name_or_title>
      <organization>University Hospitals Coventry &amp; Warwickshire NHS Trust</organization>
      <phone>02476964000 ext 25871</phone>
      <email>cyprian.mendonca@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

